Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11406698-B2
Publication Date
2022-08-09
Expiration Date
Abstract
The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.
Core Innovation
The invention relates to immunogenic compositions comprising structural antigen(s) of Zika virus and structural antigen(s) of Chikungunya virus, formulated with a pharmaceutically acceptable buffer. The Zika virus structural antigen comprises an amino acid sequence encoded by SEQ ID NO: 1 or SEQ ID NO: 2, or as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and the Zika virus and the Chikungunya virus are subjected to inactivation such that the composition is rendered non-infectious.
In another aspect, the invention provides immunogenic compositions comprising recombinant antigens derived from structural proteins of Zika virus and recombinant antigens derived from structural protein nucleic acid of a Chikungunya virus. The composition elicits an immune response to Zika virus and Chikungunya virus in a mammal.
In a further aspect, the invention discloses an immunogenic composition comprising an antigen obtained or derived from a Zika virus and a pharmaceutically acceptable buffer, where the antigen is rendered non infectious through inactivation and/or is recombinantly engineered from the nucleic acid of a Zika virus. The antigen contains the amino acid sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4.
Claims Coverage
The independent claims present three inventive features centered on immunogenic compositions with Zika virus antigen sequences defined by SEQ ID NO: 1/2/3/4, combined with Chikungunya structural antigen or Chikungunya structural protein nucleic acid, and formulated in a pharmaceutically acceptable buffer.
Zika and Chikungunya non-infectious structural antigen immunogenic composition
An immunogenic composition comprising a structural antigen of Zika virus and a structural antigen of Chikungunya virus, wherein the structural antigen of Zika virus comprises an amino acid sequence encoded by SEQ ID NO: 1 or SEQ ID NO: 2 or the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4; a pharmaceutically acceptable buffer; wherein the Zika virus and the Chikungunya virus are subjected to inactivation such that the composition is rendered non-infectious.
Recombinant Zika structural protein antigens with Chikungunya recombinant antigens
An immunogenic composition comprising one or more recombinant antigens of a structural protein of a Zika virus and one or more recombinant antigens of a structural protein nucleic acid of a Chikungunya virus; a pharmaceutically acceptable buffer; wherein the structural protein of Zika virus comprises an amino acid sequence encoded by SEQ ID NO: 1 or SEQ ID NO: 2 or the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
Zika antigen composition with SEQ ID NO 3 and/or SEQ ID NO 4 rendered non-infectious or recombinant engineered
An immunogenic composition comprising an antigen obtained or derived from a Zika virus, and a pharmaceutically acceptable buffer, wherein the antigen is rendered non infectious through inactivation and/or is recombinantly engineered from the nucleic acid of a Zika virus; and the antigen contains the amino acid sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4.
The claim coverage centers on immunogenic compositions that present Zika antigen amino acid sequences defined by SEQ ID NO: 1/2/3/4, combined with Chikungunya structural antigen or structural protein nucleic acid, and rendered non-infectious via inactivation or recombinant engineering.
Stated Advantages
Elicits an immune response to Zika virus and Chikungunya virus in mammals.
Elicits an immune response to infection by Zika virus and Chikungunya virus in a mammal.
Renders the composition non-infectious through inactivation.
Documented Applications
No documented applications found
Interested in licensing this patent?